Clinical Trial Update: A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Gammagard Liquid (intravenous immunoglobulin 10%) to prevent infections in adults with multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency
• Multiple Myeloma

Drugs mentioned

• Gammagard Liquid (intravenous immunoglobulin (IVIG) 10% solution)

Snippet

Sponsor: Takeda | Conditions: Multiple Myeloma, Secondary Immunodeficiency | Phase 3 | Status: RECRUITING